CN101801390B - 针对爱泼斯坦-巴尔病毒相关疾病的药剂 - Google Patents
针对爱泼斯坦-巴尔病毒相关疾病的药剂 Download PDFInfo
- Publication number
- CN101801390B CN101801390B CN2008801062690A CN200880106269A CN101801390B CN 101801390 B CN101801390 B CN 101801390B CN 2008801062690 A CN2008801062690 A CN 2008801062690A CN 200880106269 A CN200880106269 A CN 200880106269A CN 101801390 B CN101801390 B CN 101801390B
- Authority
- CN
- China
- Prior art keywords
- epstein
- barr virus
- cell
- medicament
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 27
- 201000010099 disease Diseases 0.000 title claims abstract description 19
- 241000701044 Human gammaherpesvirus 4 Species 0.000 title claims description 38
- 238000000034 method Methods 0.000 title description 28
- 238000012216 screening Methods 0.000 title description 17
- 239000003814 drug Substances 0.000 claims abstract description 57
- 241000700605 Viruses Species 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 10
- 229940035893 uracil Drugs 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 25
- 239000013612 plasmid Substances 0.000 abstract description 22
- 230000003013 cytotoxicity Effects 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 4
- 101000800463 Homo sapiens Transketolase Proteins 0.000 abstract 2
- JKQGUWCMZVJBEK-LQBCMXCNSA-N 1-[(2r,3r,4s,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@@](F)(O)[C@H](O)[C@@H](CO)S1 JKQGUWCMZVJBEK-LQBCMXCNSA-N 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 55
- 102000006601 Thymidine Kinase Human genes 0.000 description 25
- 108020004440 Thymidine kinase Proteins 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 101150003725 TK gene Proteins 0.000 description 13
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 229960002963 ganciclovir Drugs 0.000 description 8
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 208000037581 Persistent Infection Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000007541 cellular toxicity Effects 0.000 description 5
- 210000002751 lymph Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 4
- 229960002555 zidovudine Drugs 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- -1 2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl Chemical group 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GBBJCSTXCAQSSJ-JVZYCSMKSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GBBJCSTXCAQSSJ-JVZYCSMKSA-N 0.000 description 1
- GCQYYIHYQMVWLT-BDNRQGISSA-N 5-(2-bromoethenyl)-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 GCQYYIHYQMVWLT-BDNRQGISSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 1
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/05—Epstein-Barr virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
1-(2-氟-4-硫代-β-D-阿拉伯呋喃糖基)-5-甲基尿嘧啶发挥抗EB病毒活性，且作为EB病毒相关疾病的预防或治疗剂而有效。向TK缺损细胞中分别导入表达EB病毒-TK与人体TK的质粒，以产生分别导入了质粒的两种细胞。使用导入了各质粒的两种细胞，筛选出在导入了表达EB病毒-TK的质粒的细胞中显示细胞毒性，而在导入了人体TK的细胞中不显示毒性的药剂，由此可以筛选出特别发挥抗EB病毒活性的药剂。
Description
技术领域
本发明涉及一种抗爱泼斯坦-巴尔病毒(Epstein-Barr virus)剂、以及针对EB病毒相关疾病的药剂及该药剂的有效筛选法。
背景技术
虽然比率不高，但一般认为EB病毒会引起B淋巴瘤、鼻咽癌、胃癌等各种肿瘤。针对这样的肿瘤，在不适合进行手术的情况下的治疗法，会投予一般的抗癌剂，但这不一定是有效的治疗法。另外，报告有抗病毒剂更昔洛韦(ganciclovir)作为肿瘤治疗药的候选(非专利文献1)，但其效果较弱，尚不实用。
此外，实验室也尝试了使用源自与EB病毒相关的单纯疱疹病毒(herpes simplex virus)的胸苷磷酸化酶(thymidine phosphorylase)(胸苷激酶，thymidine kinase，TK)的基因治疗法，但还不能应用于患者。
另一方面，1-(2-氟-4-硫代-β-D-阿拉伯呋喃糖基)-5-甲基尿嘧啶作为对疱疹病毒等具有较弱的抗病毒活性的化合物而广为人知(非专利文献2、专利文献1以及专利文献2)，但完全不了解该化合物对于EB病毒的抗病毒活性、及对于由EB病毒所引起的肿瘤的效果。
非专利文献1：抗菌物和化学疗法期刊(Antimicrob.AgentsChemother)2001；45(7)：2082-91
非专利文献2：抗病毒药杂志(Antiviral Res.)1998；39(2)129-37
专利文献1：国际公开编号WO91/04982
专利文献2：日本专利特开平10-87687号公报
发明内容
因此，本发明的目的在于找出一种抗EB病毒剂、以及对于EB病毒相关疾病具有显着效果的药剂。
先前，尚未报告找出针对EB病毒相关疾病的药剂的有效筛选方法。因此，本发明者们首先确立有效的筛选法，并尝试了使用该筛选法来找出对于EB病毒相关疾病具有显着效果的药剂。其结果为，利用肿瘤细胞中所存在的源自EB病毒的TK，确立通过该TK而特异性磷酸化后对细胞显示出毒性的药剂的筛选法，并且使用该筛选法对各种化合物进行筛选，结果发现1-(2-氟-4-硫代-β-D-阿拉伯呋喃糖基)-5-甲基尿嘧啶显示出抗EB病毒活性以及对于EB病毒相关疾病的显着效果。
因此，本发明是基于所述见解而完成的，如以下的[1]～[4]所示。
[1]一种抗爱泼斯坦-巴尔(EB)病毒剂，其特征在于：含有1-(2-氟-4-硫代-β-D-阿拉伯呋喃糖基)-5-甲基尿嘧啶、它的盐或者它们的水合物或溶剂合物作为有效成分。
[2]一种EB病毒相关疾病的预防或治疗剂，其特征在于：含有1-(2-氟-4-硫代-β-D-阿拉伯呋喃糖基)-5-甲基尿嘧啶、它的盐或者它们的水合物或溶剂合物作为有效成分。
[3]如所述[2]的预防或治疗剂，其特征在于：EB病毒相关疾病是由EB病毒所引起的肿瘤、或者急性或慢性EB病毒感染症。
[4]一种发挥抗EB病毒活性的药剂的筛选方法，其特征在于：向胸苷激酶(TK)缺损细胞中分别导入表达EB病毒-TK基因与人体TK基因的质粒(plasmid)，以产生分别导入了质粒的两种细胞，使用导入了各质粒的两种细胞，筛选出在导入了表达EB病毒-TK基因的质粒的细胞中显示细胞毒性，而在导入了表达人体TK基因的质粒的细胞中不显示毒性的药剂。
[发明的效果]
本发明的药剂只对表达EB病毒-TK基因的细胞显示细胞毒性，而对表达人体TK基因的细胞不显示毒性，因此可以期待抗EB病毒效果以及对于EB病毒相关疾病的预防及治疗效果、和副作用的减少，因而本发明的药剂作为由EB病毒所引起的疾病，例如EB病毒的急性或慢性感染症，由EB病毒所引起的恶性肿瘤等的预防、治疗药而有用。
另外，本发明的筛选方法可以利用源自EB病毒的TK，来筛选出通过该TK而特异性磷酸化后对细胞显示出毒性的药剂，因此作为筛选出发挥抗EB病毒活性的药剂的方法而有用。
附图说明
图1是示意性地表示本发明的筛选法的概要的图。
图2是表示本发明药剂对于B淋巴球中的EB病毒DNA量的效果的图。
具体实施方式
以下，首先对本发明的筛选方法进行说明，其次对利用该筛选方法所选择出的本发明的药剂进行说明。
(1)本发明的筛选方法
本发明的方法如上所述，涉及如下方法：向TK缺损细胞中分别导入表达EB病毒-TK基因与人体TK基因的质粒，以产生分别导入了质粒的两种细胞，使用导入了各质粒的两种细胞，筛选出在导入了表达EB病毒-TK基因的质粒的细胞中显示细胞毒性，而在导入了表达人体TK基因的质粒的细胞中不显示毒性的药剂。
TK缺损细胞优选TK缺损人体肿瘤细胞，例示包含TK缺损人体骨肉瘤细胞(143B)等。这样的细胞可以从美国菌种保藏中心(American TypeCulture Collection，ATCC)等处购入，所例示的143B细胞注册为ATCCCRL-8303。
表达EB病毒-TK基因或人体TK基因的质粒载体(plasmid vector)可以包含如下的质粒：该质粒如图1所示，具有用于选择的适当的抗生素抗性与对EB病毒-TK或人体TK进行编码的基因，其中对EB病毒-TK或人体TK进行编码的基因在启动子(promoter)的下游以能够表达的状态来连结。
对EB病毒-TK或人体TK进行编码的基因已被克隆(cloning)，它的碱基序列可以使用美国国家生物技术信息中心(National Center forBiotechnology Information，NCBI)的数据库(date base)进行检索。因此，可以基于NCBI的数据库信息，利用常规方法来制备对EB病毒-TK以及人体TK进行编码的基因。
其次，利用常规方法连结以上所制备的TK基因以及具有适当的抗生素抗性且具有例如源自巨细胞病毒(cytomegalovirus，CMV)的启动子与终止子(terminator)的质粒。具体而言，对EB病毒-TK或人体TK进行编码的基因质粒是利用常规方法连结至Promega公司制造的质粒pCI-neo真核表达载体(pCI-neo Mammalian Expression Vector)的启动子的下游的多克隆区域(multicloning region)，以成为能够表达对EB病毒-TK或人体TK进行编码的基因。
将所制备的质粒载体基因导入到所述TK缺损细胞中。基因导入可以根据常规方法(美国国家科学院学报(Proc.Natl.Acad.Sci.USA)1987Nov；84(21)：7413-7)来进行。
使用导入了以所述方式制备的EB病毒-TK与人体TK的各基因的两种细胞，筛选出在导入了EB病毒-TK基因的细胞中显示细胞毒性，而在导入了人体TK基因的细胞中不显示毒性的药剂，由此可以筛选出发挥抗EB病毒活性的药剂。特别是通过求出将被检药剂的细胞生存率抑制为50％的各浓度(CC50)，并求出各浓度的比来作为选择指数(Selectivity Index，SI)，则能够以数值来表示药剂的选择性毒性。
(2)本发明的药剂
本发明药剂的有效成分是1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)-5-甲基尿嘧啶(别名：1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)胸腺嘧啶)。该化合物是公知的化合物，能够以文献中的公知方法或者应用该公知方法的方法来制备(参照非专利文献2、专利文献1或专利文献2等)。该化合物也可以是盐、水合物或溶剂合物的形态。这样的盐可以例示盐酸盐或硫酸盐等酸加成物。另外，水合物或溶剂合物可以例示相对于1分子的所述化合物或它的盐，附着有0.1分子～3.0分子的水或溶剂的水合物或溶剂合物。此外，所述化合物中也可以包含互变异构体等各种异构体。
本发明的药剂作为抗EB病毒剂、EB病毒相关疾病的预防或治疗剂而有效。EB病毒相关疾病可以列举由EB病毒所引起的肿瘤、或者急性或慢性EB病毒感染症，由EB病毒所引起的肿瘤例如可以列举B淋巴瘤、鼻咽癌、胃癌等。
本发明药剂的投予量根据患者的年龄、体重、疾病、患者病情的严重程度、药物的耐受性、投予方法等而有所不同，可以综合这些条件来适当决定，通常是从每天为0.001mg/kg体重～1000mg/kg体重的范围内选择，优选从0.01mg/kg体重～100mg/kg体重的范围内选择，并且一次或分成多次来投予。投予方法可以通过经口、非经口、经肠、局部投予等任一种途径来投予。
制成制剂时，可以使用通常所使用的制剂用载体、赋形剂、其他添加剂。载体可以例示乳糖、高岭土(kaolin)、蔗糖、结晶纤维素(crystalline cellulose)、玉米淀粉(corn starch)、滑石粉(talc)、琼脂、果胶(pectine)、硬脂酸(stearic acid)、硬脂酸镁(magnesium stearate)、卵磷脂(lecithin)、氯化钠等个体状载体，甘油(glycerin)、花生油、聚乙烯吡咯烷酮(polyvinylpyrrolidone)、橄榄油(olive oil)、乙醇 (ethanol)、苯甲醇(benzyl alcohol)、丙二醇(propylene glycol)、水等液状载体。剂型可以采用任意的形态，例如当使用个体状载体时，可以例示片剂、散剂、颗粒剂、胶囊剂、栓剂、口含片剂等，当使用液状载体时，可以例示糖浆(syrup)、乳液、软胶胶囊(softgelatin capsule)、乳膏(cream)、凝胶(gel)、糊剂(paste)、喷剂(spray)、注射剂等。
实施例
以下，列出实施例来具体说明本发明，但明确的是本发明并不限定于该实施例。
实施例
(1)细胞株的建立
将通过EB病毒-TK而受到特异性磷酸化后对细胞显示出毒性的药剂的筛选法的概要示于图1。
首先，基于NCBI的数据库信息来设计引物(primer)，并从B95a细胞(病毒学期刊(J.Virol.)1990；64(2)：700-5)中提取脱氧核糖核酸(Deoxyribonucleic Acid，DNA)，然后通过聚合酶链式反应(Polymerase Chain Reaction，PCR)法将EB病毒的TK基因放大，并将它克隆到表达质粒载体pCI-neo的多克隆区域(pCI-EB-TKneo)。同样地，将人体TK基因也通过PCR法来放大，并进行克隆(pCI-huTKnco)。决定碱基序列后确定所克隆的基因片段是否为目标基因。
接着，利用脂质体转染法(lipofection)(美国国家科学院学报(Proc.Natl.Acad.Sci.USA)1987 Nov；84(21)：7413-7)，将表达EB病毒-TK基因或人体TK基因的质粒载体，即分别为pCI-EB-TKneo或pCI-huTKnco导入到TK缺损人体骨肉瘤细胞(143B)中，并利用新霉素(neomycin)来选择出导入了质粒的细胞。
使用导入了EB病毒-TK基因(143B/EB病毒-TK)与导入了人体TK基因(143B/hu-TK)的这两种细胞，进行在导入了EB病毒-TK基因的细胞中显示毒性，而在导入了人体TK基因的细胞中不显示毒性的药 剂的筛选。
(2)药剂敏感性的决定
143B/EB病毒-TK、143B/hu-TK、143B TK(-)细胞以及EBV持续感染细胞的药剂敏感性是由各药剂的细胞毒性所决定的。即，向加入了100μl的各种浓度的各药剂的96孔平底培养板中添加细胞(143B/EB病毒-TK，143B/hu-TK，143B TK(-)细胞：5×104细胞/100μl，EB病毒持续感染细胞：20×104细胞/100μl)。培养5日后，利用MTT[3-(4，5-二甲基噻唑-2-基)-2，5-二苯基四氮唑溴盐]分析来决定生存细胞数。此外，所测试的药剂的细胞毒性是以将细胞生存率抑制为50％的浓度(CC50)来表示。
(3)药剂的效果
利用MTT分析，来研究过去报告为由EB病毒-TK引起磷酸化的核酸衍生物(叠氮胸苷(azidothymidine，AZT)、5-氟-2′-脱氧尿苷(5-fluoro-2′-deoxyuridine，5FdU)、阿昔洛韦(aciclovir，ACV)、1-β-D-阿拉伯呋喃糖基-5-溴乙烯基尿嘧啶(1-β-D-arabinofuranosyl-5-bromovinyl uracil，BVaraU)、更昔洛韦(GCV)、5-溴乙烯基-2′-脱氧尿苷(5-bromovinyl-2′-deoxyuridine，BVDU))是否对表达EB病毒-TK基因的143B/EB病毒-TK显示选择性毒性。另外，对于作为与本发明的化合物结构类似的核酸衍生物的1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)尿嘧啶(1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)uracil，FMAU)、1-(C-氰基-2-脱氧-呋喃核糖基)胸腺嘧啶(1-(C-cyano-2-deoxy-ribofuranosyl)thymine，1′-CN-dT)、β-D-2-亚甲基-4-硫代-β-D-赤-戊呋喃糖基)胸腺嘧啶(β-D-2-methylene-4-thio-β-D-erythro-pentofuranosyl)thymine，4′-S-DMDT)、1-(2-脱氧-4-硫代-β-D-阿拉伯呋喃糖基)胸腺嘧啶(1-(2-deoxy-4-thio-β-D-arabinofuranosyl)thymine，4′-S-araT)、1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)胞嘧啶(1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosy)cytosine，4′-S-FMAC)也同样进行了研究。
其结果如表1所示，除本发明的药剂以外，无法找出对143B/EB病毒-TK细胞显示选择性毒性的药剂。另外，对所述核酸衍生物以外的130种核酸衍生物同样进行了筛选，但无法找出显示显着效果的药剂。
(4)本发明药剂的效果
与所述(3)同样，利用MTT分析来查明本发明药剂对于143B/EB病毒-TK细胞以及143B/hu-TK(人体TK)细胞的细胞毒性，结果如表1所示，本发明药剂对于143B/EB病毒-TK细胞显示出最高的选择指数(SI：2700倍或2700倍以上)，但在300μM下对143B/hu-TK细胞完全不显示毒性。
[表1]
表1：各种药剂的细胞毒性效果
(5)本发明药剂对于EB病毒感染癌细胞的效果
利用MTT分析来查明本发明药剂对于作为EB病毒感染癌细胞的NC37 细胞等的细胞毒性效果。其结果如表2所示，在表达EB病毒-TK基因的NC37细胞中，本发明药剂比现有的药剂GCV显示出10倍或10倍以上的效果。但是，在不表达EB病毒-TK基因的细胞中均无效果。
[表2]
表2：对于EB病毒感染癌细胞的细胞毒性效果
(6)对于急性感染的效果
从健康人的血液中分离出B淋巴球。在本发明药剂的存在下使该B淋巴球感染EB病毒，进行2周的培养后。然后，对感染B细胞进行回收、清洗，接着提取DNA。通过实时PCR来对该B淋巴球中的EB病毒DNA量进行定量，并将它作为病毒复制数。将具有代表性的2例(PBMC#1287以及PBMC#5926)的结果示于图2。如图2所示，可以明确本发明药剂使B淋巴球中的EB病毒DNA量下降，且新的感染也受到抑制。
(7)对于慢性活动性EB病毒感染症细胞的效果
慢性活动性EB病毒感染症是EB病毒感染自然杀伤T细胞(NaturalKiller T cells，NKT细胞)而非B细胞的预后不良的感染症。从日本人类科学研究资源库(Human Science Research Resources Bank)购入该慢性感染细胞株KAI3细胞(临床与实验免疫学(Clin.Exp.Immunol.)1999 Mar；115(3)：385-92)，并利用MTT分析来研究本发明药剂的效果。此外，使用GCV来作为对照药剂。其结果如表3所示，本发明药剂与GCV相比，明显地显示出较高的效果。
这样一来，可以明确本发明药剂在所述效果方面，具有与迄今为止所报告的GCV相比优异10倍或10倍以上的效果，并且可以认为本发明药剂只对表达EB病毒-TK基因的细胞显示细胞毒性，且本发明药剂可以不论急性、慢性而排除EBV感染细胞。
[表3]
表3：对于慢性活动性EB病毒感染症细胞的效果
产业上的可利用性
本发明的药剂作为针对由EB病毒所引起的疾病的预防、治疗药而有用，例如EB病毒的急性或慢性感染症，由EB病毒所引起的恶性肿瘤等，且该预防、治疗药的副作用降低。另外，本发明的筛选方法作为筛选特别发挥抗EB病毒活性的药剂的方法而有用。
Claims (3)
1.含有1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)-5-甲基尿嘧啶或它的盐作为有效成分在制备抗爱泼斯坦-巴尔病毒剂中的用途。
2.含有1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)-5-甲基尿嘧啶或它的盐作为有效成分在制备爱泼斯坦-巴尔病毒相关疾病的预防或治疗剂中的用途。
3.根据权利要求2所述的用途，其特征在于：爱泼斯坦-巴尔病毒相关疾病是由爱泼斯坦-巴尔病毒所引起的肿瘤、或者急性或慢性爱泼斯坦-巴尔病毒感染症。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-233552 | 2007-09-10 | ||
| JP2007233552 | 2007-09-10 | ||
| PCT/JP2008/066175 WO2009034945A1 (ja) | 2007-09-10 | 2008-09-08 | エプスタイン・バールウイルス関連疾患に対する薬剤およびそのスクリーニング法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101801390A CN101801390A (zh) | 2010-08-11 |
| CN101801390B true CN101801390B (zh) | 2012-11-14 |
Family
ID=40451953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801062690A Active CN101801390B (zh) | 2007-09-10 | 2008-09-08 | 针对爱泼斯坦-巴尔病毒相关疾病的药剂 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100330563A1 (zh) |
| EP (1) | EP2189161B1 (zh) |
| JP (1) | JP5326173B2 (zh) |
| CN (1) | CN101801390B (zh) |
| CA (1) | CA2698645A1 (zh) |
| WO (1) | WO2009034945A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6719369B2 (ja) * | 2016-05-13 | 2020-07-08 | 富士フイルム株式会社 | ２’−フルオロ−５−メチル−４’−チオアラビノウリジンの製造方法及びその一部の工程を含む方法 |
| TWI773520B (zh) * | 2021-09-07 | 2022-08-01 | 博訊生物科技股份有限公司 | 用於藥物篩檢的細胞和藥劑分注裝置及其方法 |
| US11761974B2 (en) | 2021-11-01 | 2023-09-19 | Drsignal Biotechnology Co., Ltd. | Cell and medicament dispensing device for drug screening and method thereof |
| WO2023182460A1 (ja) * | 2022-03-24 | 2023-09-28 | 学校法人 聖マリアンナ医科大学 | 慢性活動性Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス感染症（ＣＡＥＢＶ）の検出方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234534A (en) * | 1989-07-17 | 1994-12-22 | Univ Birmingham | Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor |
| IE74701B1 (en) | 1989-10-04 | 1997-07-30 | Univ Birmingham | Further antiviral pyrimidine nucleosides |
| US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
| JPH1087687A (ja) | 1996-04-09 | 1998-04-07 | Yamasa Shoyu Co Ltd | ５−置換−１−（２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノシル）ウラシル |
| EP1569658A4 (en) * | 2001-12-20 | 2007-05-30 | Pharmassett Ltd | TREATMENT OF EPSTEIN-BARR VIRUS, INFECTION WITH KAPOSI-ASSOCIATED SARCOMA HERPESVIRUS AND ABNORMAL CELL PROLIFERATION |
| JP4729836B2 (ja) * | 2003-03-28 | 2011-07-20 | Ｔｄｋ株式会社 | 磁気記憶セルおよび磁気メモリデバイスならびに磁気メモリデバイスの製造方法 |
-
2008
- 2008-09-08 CA CA2698645A patent/CA2698645A1/en not_active Abandoned
- 2008-09-08 US US12/677,116 patent/US20100330563A1/en not_active Abandoned
- 2008-09-08 JP JP2009532175A patent/JP5326173B2/ja active Active
- 2008-09-08 CN CN2008801062690A patent/CN101801390B/zh active Active
- 2008-09-08 WO PCT/JP2008/066175 patent/WO2009034945A1/ja active Application Filing
- 2008-09-08 EP EP08830964A patent/EP2189161B1/en not_active Not-in-force
-
2012
- 2012-04-16 US US13/447,727 patent/US20120225837A1/en not_active Abandoned
Non-Patent Citations (3)
| Title |
|---|
| Gang-Qing Yao,et al.Inhibition of Epstein-Barr Virus Replication by a Novel L-Nucleoside, 2’-Fluoro-5-methyl-β-L-arabinofuranosyluracil.《Biochemical Pharmacology》.1996,第51卷第941-947页. * |
| Haruhiko Machida,et al..Anti-herpesvirus activity profile of 4’-thioarabinofuranosyl purine and uracil nucleosides and activity of 1-β-D-2’-fluoro-4’-thioarabinofuranosyl guanine and 2,6-diaminopurine against clinical isolates of human cytomegalovirus.《Antiviral Research》.1998,第39卷第129–137页. * |
| HaruhikoMachida et al..Anti-herpesvirus activity profile of 4’-thioarabinofuranosyl purine and uracil nucleosides and activity of 1-β-D-2’-fluoro-4’-thioarabinofuranosyl guanine and 2 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2009034945A1 (ja) | 2010-12-24 |
| CA2698645A1 (en) | 2009-03-19 |
| EP2189161B1 (en) | 2012-08-08 |
| CN101801390A (zh) | 2010-08-11 |
| US20100330563A1 (en) | 2010-12-30 |
| US20120225837A1 (en) | 2012-09-06 |
| WO2009034945A1 (ja) | 2009-03-19 |
| JP5326173B2 (ja) | 2013-10-30 |
| EP2189161A4 (en) | 2011-11-09 |
| EP2189161A1 (en) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations | |
| JP2023144131A (ja) | ガンマデルタｔ細胞の活性化のための方法および組成物 | |
| CN101060844B (zh) | 包含嘧啶的nnrti和rt抑制剂的组合 | |
| JP2017505623A5 (zh) | ||
| CN101801390B (zh) | 针对爱泼斯坦-巴尔病毒相关疾病的药剂 | |
| Rabaan et al. | Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies | |
| Heidari et al. | Transcriptomic analysis of host immune response in the skin of chickens infected with Marek's disease virus | |
| Laphanuwat et al. | Senescent T cells: Beneficial and detrimental roles | |
| Luo et al. | Adenovirus-mediated double suicide gene selectively kills gastric cancer cells | |
| Ni et al. | Antitumor efficacy of CRISPR/Cas9–engineered ICP6 mutant herpes simplex viruses in a mouse xenograft model for lung adenocarcinoma | |
| US20120195911A1 (en) | Method of treatment of cancer patients | |
| Xu et al. | Very virulent plus strains of MDV induce an acute form of transient paralysis in both susceptible and resistant chicken lines | |
| WO2017064558A1 (ja) | 新規免疫賦活化剤 | |
| WO2013056510A1 (zh) | 脱氧核苷与核苷组合在制备肿瘤药物中的应用 | |
| Shaw et al. | Ganciclovir and penciclovir, but not acyclovir, induce apoptosis in herpes simplex virus thymidine kinasetransformed baby hamster kidney cells | |
| Machida et al. | Anti-herpesvirus activity profile of 4′-thioarabinofuranosyl purine and uracil nucleosides and activity of 1-β-d-2′-fluoro-4′-thioarabinofuranosyl guanine and 2, 6-diaminopurine against clinical isolates of human cytomegalovirus | |
| CN112399858A (zh) | 医学用途 | |
| QAMAR et al. | An Investigation On The Antiviral Activity, Pharmacokinetic Properties, And Therapeutic Efficiency Of Hiv Infection Treatment: A Review | |
| Davis et al. | Temperature elevation synergises with and enhances the type-I IFN-mediated restriction of MPXV | |
| CN113413465B (zh) | 岩藻糖基化抑制剂在抗癌导致炎症中的应用 | |
| CN117751188A (zh) | 用于预防性和治疗性治疗的含有g-四链体的寡核苷酸 | |
| Sissolak et al. | AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART)–an African perspective | |
| Igorevna et al. | UDC 61 ROLE OF VIRUS VECTORS IN THE PROCESSES OF TRANSFER OF GENETIC MATERIAL | |
| KR20130097585A (ko) | 암치료 보조용 조성물 | |
| Kenney et al. | The Molecular Basis of Lytic Induction Therapy in Relation to Gamma herpesvirus (KSHV, EBV)-Associated, AIDS-Related Tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: UNIV KYOTO Effective date: 20130930 Owner name: EIICHI KODAMA Free format text: FORMER OWNER: YAMASA CORP. Effective date: 20130930 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130930 Address after: Japan Kyoto Sakyo District shogoin Sichuan haramachi of Kyoto University National University in 53 virus Patentee after: Kodama Eiichi Address before: Chiba County, Japan Patentee before: Yamasa Corp. Patentee before: University of Kyoto |